Please assess the completion status of the following clinical trial:

Trial Title: Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of laryngeal cancer with intention to treat by radiotherapy using a 16 fraction 3 week scheme~  * Stage I or II~* No known CNS disease~PATIENT CHARACTERISTICS:~Age:~* 20 to 80~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Hepatic function normal~Renal:~* Renal function normal~Other:~* Not pregnant or nursing~* No serious active infection requiring antibiotic therapy~* No autoimmune disease~* No known seizures~* No psychosocial factors that would preclude study compliance~* No allergies to sargramostim (GM-CSF)~* Willingness to cooperate for regular mirror examination of the larynx~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No concurrent chemotherapy~Endocrine therapy:~* No prior or concurrent corticosteroids~* No concurrent hormonal therapy~Radiotherapy:~* See Disease Characteristics~Surgery:~* No major organ allografts~Other:~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).